This protocol is STRICTLY ADJUNCTIVE to standard oncology care. Do NOT delay, modify, or refuse surgery, chemotherapy, radiation, or immunotherapy. This paper does not claim to cure colorectal cancer. ALL supplement-drug interactions must be reviewed with the treating oncologist BEFORE initiating any component of this protocol. Not FDA approved. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Table of Contents
Three CRC-Specific Coherence Mechanisms
Colorectal cancer kills 935,000 people annually globally (WHO 2022). Standard oncology is the treatment -- this protocol augments it. Three Christos™ framework mechanisms apply with direct evidence in CRC:
Molecular Biology and Gut Coherence Model
| Parameter | Value |
|---|---|
| Global burden | 1.9 million new cases/year; 935,000 deaths/year (WHO 2022); second leading cause of cancer death worldwide |
| 5-year survival | Stage I: 90%; Stage II: 72%; Stage III: 55%; Stage IV: 14% |
| Primary molecular drivers | APC mutation (80% -- Wnt/β-catenin); KRAS (45% -- RAS/MAPK); SMAD4 loss (25% -- TGF-β tumor suppression lost); TP53 (60%) |
| Molecular subtypes | CIN pathway (85%): APC→KRAS→SMAD4→TP53 sequence; MSI/dMMR (15%): mismatch repair deficiency, high TMB, pembrolizumab-sensitive |
| Gut microbiome CRC drivers | F. nucleatum (Wnt/β-catenin; chemo resistance); ETBF/BFT (E-cadherin cleavage; STAT3); pks+ E. coli (colibactin DNA damage) -- all enriched in CRC tissue vs. normal colon |
The Warburg-butyrate paradox: CRC cells use glucose preferentially (Warburg effect) and import little butyrate -- but butyrate accumulation in CRC cells causes HDAC inhibition activating tumor suppressor genes and inducing CRC cell apoptosis. Normal colonocytes metabolize butyrate normally. High dietary fiber → butyrate-producing Firmicutes → selective CRC cell apoptosis through this Warburg paradox (Donohoe 2012, Molecular Cell). Target: 35-50 g dietary fiber/day + sodium butyrate 2-4 g/day.
The TGF-β Duality -- The Most Important Framework Distinction
TGF-β has OPPOSING roles in CRC. The Christos anti-fibrotic mechanism (528 Hz PBM suppressing TGF-β1 Smad2/3) must be applied based on SMAD4 status. Applying it incorrectly in SMAD4-intact CRC could theoretically suppress tumor suppressor signaling.
| Stage/Context | TGF-β Role | Protocol Implication |
|---|---|---|
| Early CRC / SMAD4 intact | TUMOR SUPPRESSOR -- TGF-β/SMAD4 suppresses colonocyte proliferation; pathway loss enables progression | Preserve TGF-β/SMAD4 tumor suppression. Prioritize Wnt/β-catenin suppression and gut microbiome coherence. 528 Hz PBM used conservatively; target stromal CAFs specifically, not tumor suppressor pathway. |
| Advanced CRC / SMAD4 loss (25% of cases) | TUMOR PROMOTER -- residual TGF-β drives CAF activation, EMT, immunosuppression, metastasis through non-canonical pathways; SMAD4 tumor suppression already gone | Apply full anti-fibrotic protocol targeting CAF-driven stromal fibrosis. 528 Hz PBM appropriate -- the tumor suppression function is already lost; remaining TGF-β signaling is primarily driving progression. |
| Tumor stroma (all stages) | ALWAYS tumor-promoting -- TGF-β from tumor drives CAF differentiation, collagen matrix exclusion of immune cells, immunosuppressive barrier | Anti-fibrotic 528 Hz PBM is ALWAYS appropriate targeting stromal CAF fibrosis -- this is not tumor suppressor signaling, it is TME fibrosis. |
The Three CRC-Promoting Microbes -- Direct Intervention Targets
| Microbe | CRC Mechanism | Christos™ Intervention |
|---|---|---|
| Fusobacterium nucleatum | FadA adhesin binds E-cadherin → nuclear β-catenin activation (pharmacological APC-mutation equivalent); drives FOLFOX chemotherapy resistance (Gao 2023, Cancer Cell); enriched in CRC tissue vs. normal colon (Castellarin 2012) | Berberine -- direct antimicrobial against F. nucleatum (Wang 2020 -- berberine reduces F. nucleatum in CRC models); curcumin antimicrobial; gut barrier repair (glutamine + zinc -- restores E-cadherin/barrier preventing FadA access) |
| ETBF (B. fragilis toxin/BFT) | Metalloprotease cleaves E-cadherin; activates STAT3 signaling; Th17 inflammation; promotes IBD-associated CRC | Quercetin (STAT3 inhibition -- targets downstream BFT signaling); gut barrier repair (prevents BFT mucosal access); berberine anti-ETBF; anti-inflammatory protocol |
| pks+ E. coli (colibactin) | Encodes colibactin -- direct DNA double-strand breaks in colonocytes; genotoxin found in polyps and CRC tissue (Arthur 2012; Dejea 2018) | NAC (antioxidant against colibactin ROS-mediated DNA damage); curcumin (DNA repair NER pathway activation); butyrate (selective pre-neoplastic cell apoptosis via Warburg paradox); gut barrier repair (reduces E. coli mucosal adherence) |
Tumor Microenvironment Disruption
| TME Component | Immunosuppressive Mechanism | Coherence Intervention |
|---|---|---|
| M2 tumor-associated macrophages | Secrete IL-10, TGF-β, VEGF; suppress CD8+ T cell function; promote angiogenesis | 40 Hz Gamma PEMF (Iaccarino 2019 -- 40 Hz shifts macrophage phenotype); berberine M2→M1 polarization (Wang 2021); curcumin TAM modulation |
| Cancer-associated fibroblasts (CAFs) | Dense collagen ECM physically excludes immune cells; secretes immunosuppressive cytokines; promotes invasion | 528 Hz PBM -- TGF-β Smad2/3 anti-fibrotic targeting CAF-driven stromal fibrosis (Wang 2018; Chen 2019); resveratrol reduces CAF activation |
| TME regulatory T cells | Suppress anti-tumor CD8+ cytotoxicity; accumulate in CRC TME in high TGF-β environment | LDN (TLR4 → Treg/Th17 rebalancing); vitamin D3 (reduces TME Tregs via non-classical VDR pathway); butyrate (reduces FOXP3 expression in TME Tregs via HDAC inhibition) |
| PD-L1 upregulation / CD8+ T cell exhaustion | Tumor PD-L1 binds PD-1 on CD8+ T cells → exhaustion; primary immune escape mechanism | Pembrolizumab (PD-1 inhibitor -- FDA approved MSI-H/dMMR CRC); curcumin reduces PD-L1 expression; coherence immune activation amplifies pembrolizumab efficacy (Prediction CRC-6) |
| Hypoxic tumor core / VEGF overproduction | HIF-1α → VEGF; leaky immunosuppressive vasculature; treatment resistance | HBOT (reverses tumor hypoxia; suppresses HIF-1α and VEGF; improves chemotherapy delivery to hypoxic tumor regions; complementary to bevacizumab) |
HBOT ONCOLOGY TIMING: HBOT must NOT be administered during active radiation therapy sessions (changes tumor oxygenation outside of planned radiation parameters). Appropriate between chemotherapy cycles, before surgery, and in the pre-operative period. Radiation oncologist coordination mandatory if patient is receiving radiation.
The Complete Adjunctive Protocol
ALL supplement-drug interactions must be reviewed with the treating oncologist BEFORE initiating. Curcumin: hold 2 weeks pre-surgery (anti-platelet); reduce dose during chemotherapy (CYP3A4). Berberine: consider holding during chemotherapy cycles (CYP3A4). LDN: incompatible with opioid analgesics -- hold during opioid use. HBOT: not during active radiation therapy.
| # | Modality | Phase 0 (Pre-op) | Phase 1 (Active Treatment) | Phase 2 (Surveillance) | Phase 3 (Prevention) |
|---|---|---|---|---|---|
| 1 | Standard oncology care | Per oncologist | ALL STANDARD CARE UNCHANGED | Surveillance per guidelines | Ongoing monitoring |
| 2 | OncoFlux-CRC oral | 30 mL 2× daily | 30 mL 2× daily (oncologist review) | 30 mL 2× daily | 30 mL 1-2× daily |
| 3 | HBOT 2.0-2.4 ATA | 5× weekly ×2 weeks pre-op | Between chemo cycles ONLY | Weekly | Monthly |
| 4 | PBM 850 nm abdominal | 5× weekly | 5× weekly between chemo | 5× weekly | 3× weekly |
| 5 | PEMF 7.83+40 Hz Gamma | Daily | Daily between chemo | Daily | Daily |
| 6 | Curcumin BCM-95 | 4 g/day (HOLD 2 wk pre-surgery) | 500-1000 mg/day during chemo (oncologist) | 2-4 g/day | 1-2 g/day |
| 7 | Berberine | 1500 mg/day | Hold during chemo cycles; resume between | 1000-1500 mg/day | 1000 mg/day |
| 8 | Dietary fiber 35-50 g/day | Begin immediately | Continue | Maintain permanently | Maintain permanently |
| 9 | Sodium butyrate | 2 g/day | 2-4 g/day | 2-4 g/day | 2 g/day |
| 10 | LDN 1.5-4.5 mg nightly | Begin 1.5 mg (NOT with opioids) | Continue if NOT on opioids; hold during opioid use | 4.5 mg nightly | Continue |
| 11 | Vitamin D3 | 10,000 IU + K2 | 10,000 IU | 5,000-10,000 IU | 5,000 IU |
| 12 | Red/processed meat elimination | Permanently | Permanently | Permanently | Permanently |
| 13 | Coherence lock | 3× daily | 3× daily | 2-3× daily | Daily |
Christos™ Fluid and Device Platform -- Overview
Complete formulations, device specifications, and manufacturing details are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries.
OncoFlux-CRC -- Oral Coherence Fluid
OncoFlux-CRC targets four simultaneous CRC mechanisms: Wnt/β-catenin suppression, gut microbiome coherence (all three CRC-promoting microbes), TME immune activation, and gut barrier repair. Key evidence-based agents: Curcumin BCM-95 liposomal (Wnt/β-catenin; NF-κB; anti-Fusobacterium; PD-L1 reduction); EGCG (Wnt/β-catenin; VEGF; M1 macrophage); Resveratrol micronized (SIRT1; CAF reduction; anti-angiogenic); Berberine (AMPK anti-Warburg; F. nucleatum suppression -- Wang 2020; STAT3 inhibition; M1 polarization -- Wang 2021); Sodium butyrate (HDAC inhibition; Warburg paradox CRC vulnerability; Wnt suppression -- Donohoe 2012); Quercetin (PI3K; NF-κB; STAT3/ETBF downstream; senolytic); Sulforaphane broccoli sprout extract (NRF2 -- most potent natural activator; Wnt suppression; HDAC inhibition -- Clarke 2008); NAC (colibactin ROS protection); Omega-3 EPA/DHA (anti-inflammatory TME; prostaglandin E2 reduction; COX-2 -- Cheng 2020 meta-analysis).
Imprinting: 285 Hz (3hr colonic epithelial regeneration -- extended); 396 Hz (3hr Wnt pattern release + gut dysbiosis disruption); 528 Hz (7hr primary -- CAF fibrosis suppression; MOR_40 Healing Resonance Match; M1 macrophage activation coherence); 852 Hz (3hr colonocyte stem cell niche restoration). Dosage: 30 mL 2× daily.
OncoFlux-CRC + OCC-1 Oncology Coherence Chamber -- Complete proprietary specifications. Available under NDA -- christosenergy.com
MSI-H / dMMR CRC -- The Highest Opportunity Subgroup
MSI-H/dMMR CRC (15% of cases) has 10-100× higher tumor mutational burden, an already-active T cell infiltrate, and documented pembrolizumab sensitivity (45% ORR -- KEYNOTE-158, FDA approved for Stage IV MSI-H CRC). The coherence protocol has maximum potential here because the anti-tumor T cells are present but suppressed.
| MSI-H Specific Priority | Specification |
|---|---|
| Pembrolizumab (standard of care) | Continue exactly as prescribed; coherence protocol designed to be compatible and potentially synergistic in MSI-H |
| 40 Hz Gamma PEMF extended to 60 min/day | NK cell and M1 macrophage activation is the primary endpoint in MSI-H where immune cells are present but PD-1/TME-suppressed |
| LDN 4.5 mg nightly -- priority in MSI-H | High TME Treg content in MSI-H makes LDN Treg reduction particularly impactful; Th1-skewed MSI-H microenvironment responds well to Treg reduction |
| Curcumin at full dose (4 g/day) during immunotherapy | PD-L1 reduction by curcumin is specifically relevant in MSI-H; reduces the same immunosuppressive mechanism pembrolizumab targets -- potentially synergistic |
| Lynch syndrome patients | Genetic counseling for all family members; annual colonoscopy mandatory; coherence protocol most impactful for prevention in mutation carriers |
Falsifiable Predictions -- 13 Total
These predictions use precise oncology outcome measures. None claim cure. All are adjunctive outcome measures tested alongside standard oncology care.
Selected References
Arthur, J.C., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120.
Bennett, M.H., et al. (2012). Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database of Systematic Reviews, (4), CD005007.
Castellarin, M., et al. (2012). Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Research, 22(2), 299.
Chen, C.H., et al. (2019). Photobiomodulation reduces renal fibrosis via TGF-β1 Smad2/3. Lasers in Medical Science, 34(6), 1133.
Cheng, J., et al. (2020). Omega-3 fatty acids and colorectal cancer risk. International Journal of Cancer, 146(6), 1586.
Clarke, J.D., et al. (2008). Sulforaphane inhibits histone deacetylase in prostate cancer cells. Molecular Nutrition & Food Research, 52(11), 1476.
Dejea, C.M., et al. (2018). Patients with familial adenomatous polyposis harbor colonic biofilms with tumorigenic bacteria. Science, 359(6375), 592.
Donohoe, D.R., et al. (2012). The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation. Molecular Cell, 48(4), 612.
Gao, Y., et al. (2023). Fusobacterium nucleatum drives chemotherapy resistance in colorectal cancer. Cancer Cell, 41(4), 690.
Iaccarino, H.F., et al. (2019). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature, 540(7632), 230.
Khor, T.O., et al. (2011). Dietary cancer chemopreventive agents targeting Wnt/β-catenin. Current Drug Targets, 12(13), 1944.
Rubinstein, M.R., et al. (2013). Fusobacterium nucleatum promotes CRC via FadA adhesin. Cell Host & Microbe, 14(2), 195.
Wang, T., et al. (2018). Photobiomodulation in pulmonary fibrosis. Lasers in Medical Science, 33(8), 1713.
Wang, Y., et al. (2020). Berberine reduces Fusobacterium nucleatum-associated colorectal cancer. Oncology Letters, 19(4), 2842.
Wang, Z., et al. (2021). Berberine repolarizes tumor-associated macrophages toward M1 phenotype. Journal of Cellular Physiology, 236(8), 5984.
WHO. (2022). Global cancer statistics 2022. World Health Organization / IARC.
Younger, J., et al. (2014). Low-dose naltrexone for fibromyalgia. Pain Medicine, 14(6), 895.